At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world. The demand for high-quality health economic and outcomes research (HEOR) and real-world evidence (RWE) to support drug development, health technology assessment/access decisions, product differentiation, and clinical decision making continues to increase. The purpose of the Health Economics and Outcomes Research (HEOR) team is to accelerate equitable patient access and transform healthcare delivery through the execution and communication of bold, high-impact science. We are looking for talented, energetic, creative, diverse, influential, and collaborative team members to join the HEOR team and Team Lilly. Clinical Outcomes Assessment (COA) involves scientific assessment of the patient voice throughout the lifecycle of drug development. Development and establishment of fitness-for-purpose clinical outcomes assessments (COAs), including Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Performance Outcomes (PerfOs), and Observer-Reported Outcomes (ObsROs) is a key capability of COA. COA also encompasses the assessment of the patient voice as it relates to patient engagement, shared decision-making, patient activation, adherence, patient preferences, and other patient-centered assessments aimed at improving patient outcomes in real-world practice. The Director sits within the HEOR Central team and is responsible for supporting and contributing to COA capability, collaborating with cross-HEOR teams focused on measuring and translating patient experience through rigorous scientific methods. The Director supports delivery of the overall COA strategy for HEOR and Lilly, contributing to the assessment of patient-centered outcomes across all phases of development. This involves providing scientific and strategic support to build capabilities for assessing and understanding the patient voice and contributing to the development of patient-focused product- and disease-state-specific strategies across the portfolio. This includes partnerships with cross-functional (e.g., regulatory) and HEOR therapeutic area scientists to support COA- and RWE-based label claims (FDA, EMA, and other geographies), and to contribute to benefit-risk patient-focused assessments in collaboration with Global Patient Safety (GPS). In addition, the Director supports the HEOR evidence needs (e.g., RWE, COAs, early economic modeling, targeted literature research) for selected disease states and products in Lilly's early-phase portfolio, particularly in neuroscience, including contributing to and executing the HEOR research agenda. The Director will collaborate with early-phase cross-functional teams — including early clinical development, new product planning, value and access, and medical affairs — to support early-phase disease-state HEOR strategy and deliver HEOR projects.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree
Number of Employees
5,001-10,000 employees